SavedAdd your journal

Journals / Journal of Microbiology and Infectious Diseases / 2014 / Cilt: 4 - Sayı: 3

Daptomycin and tigecycline susceptibility of vancomycin resistant enterococci isolated from rectal swab cultures

Rektal sürüntü kültürlerinden izole edilen vankomisin dirençli enterokok suşlarının daptomisin ve tigesiklin duyarlılıkları

Çiğdem Ataman HATİPOĞLU
Hatice Uludağ ALTUN
Sami KİNİKLİ
Ali Pekcan DEMİRÖZ
Şerife ALTUN
Cemal BULUT
Pages
107–110
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

J Microbiol Infect Dis 2014; 4(3): 107-110

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Vancomycin resistant enterococci (VRE) are important healthcare associated multidrug resistant organisms because of their easily spread in the hospital environment, difficulty to cure and high mortality rate.
📊
Key Findings & Data:Methods: Sixty non-duplicate VRE strains isolated from rectal swabs of hospitalized patients between October 2010 and February 2013 at Ankara Training and Research Hospital were included into the study.
💡
Conclusion & Impact:J Microbiol Infect Dis 2014; 4(3): 107-110
🔬Design:Research Article
📍Scope:2010 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Vancomycin resistant enterococci (VRE) are important healthcare associated multidrug resistant organisms because of their easily spread in the hospital environment, difficulty to cure and high mortality rate. The aim of this study was to evaluate in vitro activity of daptomycin and tigecycline against VRE strains isolated from rectal swab samples of hospitalized patients. Methods: Sixty non-duplicate VRE strains isolated from rectal swabs of hospitalized patients between October 2010 and February 2013 at Ankara Training and Research Hospital were included into the study. Ankara Training and Research Hospital in Ankara in Turkey is a 600-bed, tertiary care, teaching hospital. Minimum inhibitory concentration (MIC) values of daptomycin and tigecycline were determined by E-test method (bioMerieux, France).Results: All of the strains were susceptible to daptomycin, three of them (5%) were resistant to tigecycline. MIC50 and MIC90 values of daptomycin were 1.5 µg/ml and 2 µgr/ml, and of tigecycline were 0.64 µg/ml and 0.125 µg/ml, respectively.Conclusion: As a result; all of the strains were susceptible to daptomycin. On the other hand, resistance to tigecycline was exhibited by 5% of VRE isolates. Clinicians should be aware of the possibility of the emergence of tigecycline nonsusceptibility and should closely monitor tigecycline MICs of enterococci. J Microbiol Infect Dis 2014; 4(3): 107-110

Özet

Amaç: Hastane ortamında kolay yayılımı, infeksiyonlarının tedavisinin zor ve mortalite oranlarının yüksek olması nedeni ile çoklu ilaca dirençli vankomisin dirençli enterokoklar (VRE) önemli organizmalardır. Bu çalışmanın amacı; yatan hastalardan alınan rektal sürüntü örneklerinden izole edilen VRE suşlarında in vitro daptomisin ve tigesiklin duyarlılığını belirlemektir.Yöntemler: Çalışmaya Ekim 2010- Şubat 2013 tarihleri arasında Ankara Eğitim ve Araştırma Hastanesinde yatan hastaların rektal sürüntülerinden izole edilen 60 VRE suşu dahil edildi. Ankara Eğitim ve Araştırma hastanesi 600 yataklı 3. basamak bir araştırma hastanesidir. Daptomisin ve tigesiklin için minimum inhibitor konsantrasyon (MIK) değerleri E-test yöntemi (bioMerieux, Fransa) ile belirlendi.Bulgular: Tüm suşlar daptomisine duyarlı olup; üçü (%5) tigesikline dirençli saptandı. Daptomisin için MIK50 ve MIK90 değerleri sırasıyla 1.5 µgr/ml ve 2 µgr/ml saptanırken tigesiklin için 0.064 µg/ml ve 0.125 µg/ml olarak saptandı. Sonuç: Sonuç olarak; tüm suşlar daptomisine duyarlı saptandı. Diğer yandan VRE izolatlarında tigesiklin direnci %5 olarak saptandı. Klinisyenler enterokoklarda tigesiklin direncine karşı dikkatli olmalı ve tigesiklin MIK değerini yakından takip etmelidir

🔖

Cite This Article

HATİPOĞLU, Ç. A., ALTUN, H. U., KİNİKLİ, S., DEMİRÖZ, A. P., ALTUN, Ş., BULUT, C. (2022). Daptomycin and tigecycline susceptibility of vancomycin resistant enterococci isolated from rectal swab cultures. Journal of Microbiology and Infectious Diseases, Cilt: 4 - Sayı: 3, 107–110. https://ajindex.com/articles/564446

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Eliopoulos GM. Microbiology of drugs for treating multiply drugresistant gram-positive bacteria. J Infect 2009;59:17–24
  2. Diekema DJ, Jones RN. Oxazolidinone antibiotics. Lancet 2001;358:1975-1982
  3. Klare I, Witte W, Wendt C, Werner G. Vancomycin-Resistant Enterococci (VRE). Recent results and trends in development of antibiotic resistance. Bundesgesunddheitsblatt Gesundheitsforschung Gesundheitssschutz 2012;55:1387- 1400
  4. Kristich CJ, Rice LB, Arias CA. Enterococcal Infection-Treatment and Antibiotic Resistance. In: Gilmore MS, Clewell DB, Ike Y, Shankar N, eds. Enterococci: From Commensals to Leading Causes of Drug Resistant İnfection (Internet) Boston: Massachusetts Eye and Ear Infirmary 2014
  5. Entenza JM, Moreillon P. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Int J Antimicrob Agents 2009;34:8
  6. Steenbergen JN, Mohr JF, Thorne GM. Effects of daptomycin incombination with other antimicrobial agents: a review of in vitro and animal model studies. J Antimicrob Chemother 2009;64:1130-1138
  7. Kelesidis T, Humphries R, Uslan DZ, Pegues DA. Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. Clin Infect Dis 2011;52:228-234
  8. Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement, CLSI document M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA
  9. Sader HS, Jones RN. Antimicrobial susceptibility of Grampositive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007–2008). Diagn Microbiol Infect Dis 2009;65:158–162
  10. Brink AJ, Bizos D, Boffard KD, et al. Guideline: Appropriate use of tigecycline. S Afr Med J 2010;100:388-394
  11. Hoban DJ, Bouchillon SK, Johnson BM, et al. Tigecycline Evaluation and Surveillance Trial (TEST program) Group. Invitro activity of tigecycline against 6792 Gram-Negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST program 2004). Diagn Microbiol Infect Dis 2005;52:215-217
  12. Reinert RR, Low DE, Rossi F, et al. Antimicrobial susceptibility among organisms from Asia/Pasific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother 2007;60:1018-1029
  13. Wyeth Pharmaceuticals. Tygacil (tigecycline) for injection (Package Insert). 2005. Wyeth Pharm